SYMBICORT® in the Treatment of COPD (SRP COPD)

AstraZeneca

Status: Completed

Conditions: COPD

Study type: Observational

Funder types: Industry

Identifiers

NCT00564499

SRP-RB-COPD-2005/1

Details and patient eligibility

About

A Scientific Research Program to evaluate the efficacy of SYMBICORT® 320/9μg in the treatment of COPD in real life environment by General Practitioners

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients (m/f) with COPD (GOLD stadium III and IV)

Exclusion criteria

• patients who recently quit smoking (<3months)